Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Approved to Launch Oncology Drug for Cancers with RET Gene Fusions

publication date: Oct 10, 2022

Suzhou Innovent Bio was approved to launch selpercatinib, a RET kinase inhibitor in China for patients with cancers that involve rearranged during transfection (RET) gene fusions, a condition that occurs in 1-2% of NSCLC cases. Selpercatinib was discovered by Eli Lilly, an Innovent partner since 2015. Selpercatinib is a selective, potent RET kinase inhibitor with CNS activity that was approved for US use in May 2020. One month ago, the FDA granted selpercatinib second-line US approval for tumor-agnostic indications in adult patients with a RET gene fusion. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital